It was the news they had been waiting for. A Manitoba couple desperate to have kids was told they were pregnant after in-vitro fertilization.

They spent thousands of dollars on the procedure, only to learn it was all for nothing.

Carey Solomon spent two years trying to have a baby. Her first pregnancy ended with a miscarriage in 2013.

That's when she and her husband decided to try in-vitro fertilization, a process that would take its toll emotionally and financially.

“All the costs rang through when my husband and I sat down and took a look at all our receipts,” said Solomon. “We're upwards of $20,000.”

An injectable drug called Bravelle was part of that cost.

It's supposed to help women produce more eggs faster.

“My follicle production was low. I only produced two follicles, and it was a little bit confusing and heartbreaking just to know that we get one chance at this with all the money we spent,” said Solomon.

Still, Solomon got pregnant in the spring of 2015. The joy soon turned to heartache, however, when she miscarried again.

“Nine months later, I get a letter in the mail, and it's from our pharmacy,” said Solomon.

The letter from Ferring Pharmecuticals, the maker of Bravelle, said the batch of drugs Solomon took was recalled.

“It kind of started to make you think, ‘Ok that explains two follicles,’” said Solomon.

Four lots of Bravelle from Canada and theU.S. sold in 2014 and 2015 were pulled from the market.

“The drug company made a mistake and sold a drug that lacked potency and failed stability testing and was effectively a dud,” said Toronto lawyer Douglas Lennox of Klein Lawyers.

Now, Klein Lawyers has filed a class action lawsuit against the makers of Bravelle.

Since February, more than 100 Canadian customers have signed on.

The list includes Carey Solomon and eight other Manitobans.

“For us, it's personal, and for those pharmaceutical companies, it's business, and that's where everything breaks down,” said Solomon.

The company said customers may be eligible for a refund for the cost of the drug, between $2,000 and $3,000.

Solomon spent 10 times that on IVF.

“The drug company needs to do better. They need to have a better refund program to pay for the full cost of the fertility treatment,” said Lennox.

Solomon also said the company didn't do a good enough job informing patients about the recall.

She got a letter from her pharmacy and has heard others were informed by their clinic.

“Then I’ve heard that there are people who found out through the grapevine,” said Solomon.

Health Canada said since this was a voluntary recall, it's up to Ferring Pharmaceuticals to decide how it wants to inform customers.

In a statement to CTV Winnipeg, Ferring said it “issued letters to healthcare professionals, wholesalers, as well as pharmacies and fertility centres purchasing directly, advising them about the recall, and the steps taken to address and resolve the issue.”

“We asked them to direct their patients to a toll-free number, 1-866-853-2807, for any questions regarding the recall and Bravelle reimbursement program,” the statement read. “The reimbursement program was established to refund patients’ out of pocket costs for Bravelle purchased in Canada on or after June 29, 2014.”

Solomon said she called that number in February and Ferring told her she would receive a package to fill out for the refund.

To date, she said she still hasn't received that letter.

In the meantime, Solomon's running out of options as her time to conceive runs out.

“We just have been told though that our chances of conception are 1-2 per cent,” said Solomon. “We can't afford to do this again, and we are upset about it, and it's just maddening.”

Ferring said distribution of Bravelle has been halted while an analysis is carried out.